Jon Amund Kyte
- Group leader, Senior consultant; MD, PhD
- +47 2293 50 46
Publications 2024
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol (in press)
DOI 10.1002/1878-0261.13675, PubMed 38978352
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation
NPJ Breast Cancer, 10 (1), 30
DOI 10.1038/s41523-024-00638-2, PubMed 38653982
Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers
Int J Mol Sci, 25 (1)
DOI 10.3390/ijms25010586, PubMed 38203757
Correction: Jin et al. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. Int. J. Mol. Sci. 2024, 25, 586
Int J Mol Sci, 25 (18)
DOI 10.3390/ijms251810024, PubMed 39337718
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer
Mol Oncol (in press)
DOI 10.1002/1878-0261.13760, PubMed 39545921
Publications 2023
Development of a TGFβ-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy
Biomedicines, 11 (2)
DOI 10.3390/biomedicines11020459, PubMed 36830995
How I treat endocrine-dependent metastatic breast cancer
ESMO Open, 8 (2), 100882
DOI 10.1016/j.esmoop.2023.100882, PubMed 36806375
Publications 2022
Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform
Cancers (Basel), 14 (19)
DOI 10.3390/cancers14194859, PubMed 36230782
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 225
DOI 10.1186/s12967-022-03432-5, PubMed 35568909
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 317
DOI 10.1186/s12967-022-03518-0, PubMed 35841045
Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer
Mol Ther Oncolytics, 26, 189-206
DOI 10.1016/j.omto.2022.06.007, PubMed 35860008
Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers
Cancers (Basel), 14 (3)
DOI 10.3390/cancers14030571, PubMed 35158839
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Nat Med, 28 (12), 2573-2583
DOI 10.1038/s41591-022-02126-1, PubMed 36482103
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
ESMO Open, 7 (5), 100588
DOI 10.1016/j.esmoop.2022.100588, PubMed 36116420
Publications 2021
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int J Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768, PubMed 34449877
Publications 2020
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Front Immunol, 11, 572172
DOI 10.3389/fimmu.2020.572172, PubMed 33324397
Use of RNA Interference with TCR Transfer to Enhance Safety and Efficiency
Methods Mol Biol, 2115, 327-349
DOI 10.1007/978-1-0716-0290-4_18, PubMed 32006409
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
J Transl Med, 18 (1), 252
DOI 10.1186/s12967-020-02424-7, PubMed 32576225
Publications 2019
Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination
Oncoimmunology, 8 (4), e1565236
DOI 10.1080/2162402X.2019.1565236, PubMed 30906659
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750
Publications 2018
Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
Adv Radiat Oncol, 3 (2), 130-138
DOI 10.1016/j.adro.2017.12.007, PubMed 29904737
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
Oncoimmunology, 8 (2), e1537691
DOI 10.1080/2162402X.2018.1537691, PubMed 30713794
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
Oncoimmunology, 7 (11), e1457598
DOI 10.1080/2162402X.2018.1457598, PubMed 30377556
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
Cancer Immunol Res, 6 (4), 467-480
DOI 10.1158/2326-6066.CIR-17-0207, PubMed 29459477
Publications 2017
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
Breast Cancer Res, 19 (1), 120
DOI 10.1186/s13058-017-0911-9, PubMed 29137653
Publications 2016
Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation
Ecancermedicalscience, 10, 691
DOI 10.3332/ecancer.2016.691, PubMed 27994647
Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
Clin Transl Immunology, 5 (11), e109
DOI 10.1038/cti.2016.65, PubMed 27990285
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
Oncoimmunology, 5 (12), e1249090
DOI 10.1080/2162402X.2016.1249090, PubMed 28123886
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
Oncoimmunology, 5 (11), e1232237
DOI 10.1080/2162402X.2016.1232237, PubMed 27999747
Publications 2015
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Gene Ther, 22 (5), 391-403
DOI 10.1038/gt.2015.4, PubMed 25652098
Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination
Cancer Immunol Immunother, 64 (12), 1609-21
DOI 10.1007/s00262-015-1766-5, PubMed 26498005
Publications 2014
[Field cancerization of skin and mucous membranes]
Tidsskr Nor Laegeforen, 134 (18), 1769
DOI 10.4045/tidsskr.13.1454, PubMed 25273254
Publications 2013
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
Int J Cancer, 134 (1), 102-13
DOI 10.1002/ijc.28338, PubMed 23784959
[The cancer riddle is outdated]
Tidsskr Nor Laegeforen, 133 (18), 1907
DOI 10.4045/tidsskr.13.1037, PubMed 24084948
Publications 2011
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
Clin Cancer Res, 17 (21), 6847-57
DOI 10.1158/1078-0432.CCR-11-1385, PubMed 21918169
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients
Clin Cancer Res, 17 (13), 4568-80
DOI 10.1158/1078-0432.CCR-11-0184, PubMed 21586625
Publications 2010
Third International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD 2009)
Expert Rev Vaccines, 9 (2), 119-23
DOI 10.1586/erv.09.157, PubMed 20109021
[We know more than we can understand]
Tidsskr Nor Laegeforen, 130 (22), 2217
DOI 10.4045/tidsskr.10.1000, PubMed 21109831
Publications 2009
Cancer vaccination with telomerase peptide GV1001
Expert Opin Investig Drugs, 18 (5), 687-94
DOI 10.1517/13543780902897631, PubMed 19388882
[Nobel Prize for mitotic clock]
Tidsskr Nor Laegeforen, 129 (23), 2470
DOI 10.4045/tidsskr.09.1298, PubMed 19997132
Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination
Cancer Immunol Immunother, 58 (10), 1609-26
DOI 10.1007/s00262-009-0670-2, PubMed 19221745
Publications 2007
Immuno-gene therapy of cancer with tumor-mRNA transfecteddendritic cells
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 469, 1 b. (flere pag.)
BIBSYS 070189625, ISBN 978-82-8072-418-2
Publications 2006
[Cancer vaccines]
Tidsskr Nor Laegeforen, 126 (22), 2969-73
PubMed 17117197
Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells
Cancer Immunol Immunother, 55 (11), 1432-42
DOI 10.1007/s00262-006-0161-7, PubMed 16612595
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
Cancer Immunol Immunother, 56 (5), 659-75
DOI 10.1007/s00262-006-0222-y, PubMed 16947019
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
Cancer Gene Ther, 13 (10), 905-18
DOI 10.1038/sj.cgt.7700961, PubMed 16710345
Publications 2005
Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination
Cancer Gene Ther, 12 (6), 579-91
DOI 10.1038/sj.cgt.7700837, PubMed 15818380
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
Br J Cancer, 93 (7), 749-56
DOI 10.1038/sj.bjc.6602761, PubMed 16136047
Publications 1999
Resting small B cells present endogenous immunoglobulin variable-region determinants to idiotope-specific CD4(+) T cells in vivo
Eur J Immunol, 29 (12), 4043-52
DOI 10.1002/(SICI)1521-4141(199912)29:12<4043::AID-IMMU4043>3.0.CO;2-E, PubMed 10602015